You do not need to sort through it alone
However, because the control phase produced similar lipid-lowering effects in the hypercholesterolemic group, these outcomes should be interpreted with caution
Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders
The study, published Monday in the journal Nature Medicine, is one of the first big-picture looks at the benefits and risks of these new drugs, which rapidly made an impact on health care, insurance coverage, the grocery industry, and even the economy of an entire country (Denmark, where Novo Nordisk, the maker of Ozempic and Wegovy is based.) These drugs have also been given partial credit for a recent dip in obesity rates in the US, which dropped in 2023 for the first time in over a decade
Amgen has developed a GLP-1/GIP drug that is given monthly, while Intracia is working on an agent that is injected every six months
Are most people happy with their weight loss experience taking GLP 1 & GIP Based Therapies
